企业简介
团队管理
公司案例

交易日期
IMPACT theraputics is a leading biotech company, focused on DNA damage innovative drugs
Company's lead clinical stage compound is a PARP inhibitor, which can be potentially Best-in-class drug in this catagory 
The company has collaborated with many famous international and domestic pharmas in combination use for ovirian, breast and other cancers
交易背景
IMPACT therapeutics  is a typical biotech company, whose PARP inhibitor is in Phase I clincial trial in both China and Australia
Phase I trials  have showed preliminary efficacy in ovarian cancer in both China and Australia
交易过程中的挑战
PARP inhibitor is a very promising assets in cancer treatment,however, on one side, 3 have marketed in US and 1 is going to MA in the next 1 year, and on the other hand, many domestic companies are R&D PARP
Though IMPACT is top 3 fastest player in China but a lot of competitors make this area crowded 
BFC team has a broad network of VCs interested in innovative drugs so we pull many together
We help convince investors about the market leader position of IMPACT
交易结果
Decheng capital invests $20M as series C lead investor
LAV, as existing shareholder, invests $10M as well 
IMPACT is planning to be listed in Hong kang market in the future

交易日期
Genext  is the leading domestic transplant company in China with a full product coverage from transplant therapeutics, IVD to medical devices.
Genext used to be the largest distributor for Abbott, has strong sales channel and connection with 169 transplant centers in China.
In 2015, the market cap of Genext was around $95M, its sales and net profit are $21.5M and $5.2M respectively.
交易背景
交易过程中的挑战
交易结果
The deal not only helped Genext transform from a domestic distributor to an integrated company with global presence, but also enriched Genext’s product line through LSI’s strong expertise in R&D.
By proper financial engineering , BFC group helped Genext bring in top-tier investment and significantly enhance valuation. The deal further strengthened Genext’s leading position in transplant area.
After M&A integration, Genext is now geared towards IPO.

交易日期
Eutilex  is a Korea-based, clinical-stage biopharmaceutical company focused on the development of anti-tumor T cell and antibody therapeutics for the treatment of cancers and autoimmune diseases.
License Product:EU101-a preclinical-stage human monoclonal antibody agonist that binds to 4-1BB (CD137).
Eager to step into China market with a strategic Chinese partner who has strong R&D and commercialization capabilities.

交易背景
交易过程中的挑战
With sufficient fund and ideal partnership structure, the deal infused new momentum into Eutilex’s antibody and anti-tumor T cell therapy development programs, accelerated its R&D progress. Eutilex is able to explore the potential from China market.
Huahai received an exclusive license to develop and commercialize EU-101, in the P.R. China, Taiwan, Hong Kong and Macau. Huahai strengthened its arm in the field of novel drug development, and expanded its footprint in the Korean market.
After closing the deal, Eutilex’s valuation is significantly enhanced and is now prepared for  IPO in KSDAQ.

交易结果

交易日期
KBP is a globally integrated Chinese biotech company.  KBP has its clinical development center in US; Its R&D and CMC center is based in Jinan, China
KBP is the pioneer in adopting global clinical development for global filing
KBP is trying to raise the capital to finish the phase II programs globally for its two leading programs
KBP is also interested in building a global leadership team and plans to go public in the Nasdaq market

交易背景
交易过程中的挑战
交易结果
The initial financing plan was to raise $30 M to finish the KBP-5074 phase II trial in US, but the strong market demand for KPB leading to a closing of $83 M.
Advantech Capital and SDIC Venture Capital led this financing round, other investors including Sangel Capital, Ping An Ventures, Bay City Capital, GF XINDE, Efung Capital, CASH Capital, Cowin Capital Group, Korea Investment Partners, Elite Capital, 3E Bioventures Capital and Founder H Fund participated..
The company is ready for Nasdaq listing in the near future


交易日期
Shanghai Upper Biotech is a Leading POCT diagnostic companies based in Shanghai
The company has evolved in the last 15 years from a distributor to an R&D based product development company 
The company is also expanding internationally with presence in US

交易背景
Upper Biotech is a profitable company.  The company wants to expand outside of China to attract top R&D talent and to grow product sales outside of China
Upper Biotech hopes to attract a top tier international investor to help its global expansion
.
交易过程中的挑战
POCT market is expanding, but the market is very fragment. 
Quality data about the POCT in China is very limited.  Some of the most popular IVD report is also full of error.  
BFC Team has a broad network of leading IVD companies in China.  We pull some quality data together based on our investigation. 
This help convince the investors about the market leader position of Upper
.
交易结果
OrbiMed Asia will invest $15M as the series B investor 
Upper is expected to be listed in Chinese A share in 2017 
Closing is expected by the end of 2015 due to some restructuring requirement
Upper Biotech
.

交易日期
Allgens® Bongold Bone Graft Substitute technology address the non-structural bone graft market with synthetic, bioactive alternatives to patient-and cadaver-derived bone tissue.
Bonflow®Bone Augmentation Material, an injectable, polymer composite that mimics the structural characteristics of human bone, provides the basis for the fixation portfolio.
交易背景
Allgens has become a rapidly growing profitable company in China.
To help speed up its sales growth in China, Allgens needs to build a new manufacturing facility in China.
Allgens decides to raise series C round financing to help its growth.
交易过程中的挑战
One of the original founding member needs to retire and want to sell its share during this round of financing.
Due to its rapid growth, the company expect pretty high valuation.
BFC works closely with the investor to understand the market growth and its future exit potential through M&A.
交易结果
Successfully obtained three term sheets from three reputable VCs.
New Horizon Capital was chosen to be the leading investor for Allgens for this round of financing.
BFC team worked closely with the company the investor to structure the share sales before this round of financing.
The deal was closed in six months.

交易日期
REALTON is a developer of powerful and cost effective greeenlaser systems for the treatment of benign prostatic hyperplasia (BPH).
Realton's surgical laser system and fiber optic delivery device are affordable to Chinese and other developing country hospitals and patients.
交易背景
Realton's products have been approved by the CFDA, and manufactured in China.
To grasp the opportunity to develop domestic and international markets, Realton sought funding to accelerate its market expansions of the existing products and to develop new products.
交易过程中的挑战
Large medical device sales process is quite long due to long bidding process.
It takes time to ramp up revenue with such large instrument that cos $200,000/piece.
Need to help the investor understand the market uptake process in China.
Help the company recruit a top sales VP.
交易结果
As the financial advisor of Realton, BFC assisted it complete the closing of series C funding in 2012 from VCs liek Frontline Venture, OrbiMed Asia.

交易日期
RVX's a Pharmaceutical company listed on the Toronto Stock Exchange (TSX: RVX).
It is developing RVX-208, a first-in-class, small molecule selective BET bromodomain inhibitor for the potential treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer's disease, peripheral artery disease, and chronic kidney diseaseCompany.
交易背景
RVX's core product RVX-208 has basically completed Phase II clinical study; it is about to enter Phase III clinical trail; RVX needs investment for the Phase III clinical trials, and it is willing to license the Chinese rights.
Shenzhen Hepalink is a Chinese listed pharmaceutical company with 20 billion RMB market capitalization; its main business is the research, development, manufacture and sales of heparin products.
交易过程中的挑战
Found an optimal deal structure that can meet the needs of both parties.
Assisted RVX understand the registration process required by CFDA, as well as the requirements of international multi-center clinical trial.
Helped RVX understand the pharmaceutical distribution process so that a proper licensing agreement can be reached.
交易结果
BFC assisted RVX to look for partners in China, and efficiently completed the transaction within six months.
Hepalink led the CAD$50 million private placement, and subscribed $35 million common shares; Eastern Capital subscribed CAD$15 million common shares.
RVX has exclusively licensed the Chinese rights of RVX-208 to Hepalink in China, Hong Kong, Taiwan and Macau.

交易日期
The Medicine Company was founded in 1996 and is a NASDAQ-listed pharmaceutical company with 1.7 billion USD market cap.
Its main product is Angiomax, which is an injection of thrombin inhibitor, used as an anticoagulant for patients with unstable angina undergoing PTCA and as an anticoagulant for patients undergoing PCICompany.
交易背景
As the original owner of Angiomax, the Medicines Company has completed the clinical trail of Angiomax in China, and it wished to find a partners to develop the Chinese market.
SciClone is a listed company with 500 million USD market capitalization, and its main business is selling drugs in China.
交易过程中的挑战
Help the potential partners understand the complex landscape of the regulatory process and its implication of potential approval in China.
Help the potential partners understand the value of original import brand in China even in the face of generic competition.
Set the right expectation for different potential partners to keep it competitive.
交易结果
BFC assisted the Medicine Company to get six term sheets, and completed the transaction efficiently within nine months.
SciClone has got the Chinese rights of Angiomax® and Cleviprex®; the transaction included an upfront payment, a product support services fee and regulatory /commercial success milestone payments of up to an aggregate of $ 50.5 million USD.

交易日期
Ironwood  was founded in 1998, it is a Nasdaq listed pharmaceutical company with more than 1 billion USD market cap in Boston.
Ironwood's leading product candidate is linaclotide, which is for the treatment of irritable bowel syndrome with constipation(IBS-C) and chronic idiopathic constipation (CIC).
交易背景
Linaclotide had entered the clinical Phase III in Europe and the United States for the treatment of IBS-C, but had not started the clinical trial in China.
Ironwood hoped to find a partner with strong clinical competence in China.
In addition, the partner needs to be FCPA Compliance.
Economic terms is also very important to Ironwood.
交易过程中的挑战
Helped Ironwood understand the IP environment in China.
Worked with Ironwood to understand the CFDA regulatory process in China.
Mapped out the best partners with strong GI capabilities in China.
Helped the company develop a low risk partnering strategy.
交易结果
BFC helped Ironwood select AstraZeneca (China) as the most suitable strategic partners.
AstraZeneca made an upfront payment of $25 million to Ironwood.
Ironwood is also eligible for $125 million in additional commercial milestone payments from AstraZeneca contingent on the achievement of certain sales targets.

交易日期
CHIVD (Chemclin) is a leading Chinese IVD company based in Beijing. It has a strong investor base such as Siemens Venture, OrbiMedAsia, and Softbank China.
The company is a leading provider of fully-automated and semi-automated chemiluminescentsystems and fully registered chemiluminescent("CLIA") assays with the broad menu.
交易背景
CHIVD has become the clear market leader in China to lead the CLAR product sales.
CHIVD is interested in seeking international partner to build its CLAR instrumentation platform.
CHIVD is also interested in product in-licensing from global IVD companies.
交易过程中的挑战
Chinese market has a strict reimbursement policy set up by different local government bodies.
Any instrumentation targeted for the Chinese market has to meet the reimbursement environment.
In addition, quality of the product is the key as Chinese hospitals have much large sample volume and requires even high quality standard.
交易结果
BFC team worked closely with the CHIVD team to screen for different potential partners in China, US, Europe and Japan.
Developed a long term strategic partnership in Europe to build CLAR instrumentation platform.
Help maintain the working relationship with the European partner.
CHIVD’s CLAR instrumentation is the largest among all the domestic players in China.

交易日期
Agenix was founded in 1982, and was listed on the Australian Stock Exchange in 1987; it is an international biotech company. Its core product Thromboview®, mainly used to detect blood clots in humans, has completed the phase II human clinical trials the United States.
交易背景
The company wanted to focus on its IVD product and to terminate its new drug research of AGX-1009 in China and to divest the asset.
AGX-1009 is a hepatitis B new drug; Agenix completed the pre-clinical studies and was ready to apply the clinical trial application (CTA).
交易过程中的挑战
Agenix is a small Australian company that has limited understanding of Chinese market.
The company board was also very nervous about the legal environment in China.
BFC has worked with Agenix chairman and the board to develop a viable deal structure to help the company sell the asset.
交易结果
As the financial advisor of Agenix, BFC successfully help it transfer the AGX-1009 asset to Cinkate Pharmaceutical Corp.
The transaction also involved four other parties; BFC assisted Agenix successfully handle the relationship between those four parties and completed the deal.

交易日期
Icon is a global provider of outsourced development services to pharmaceutical, biotechnology and medical device industries, with ~4.7 billion $ market cap.
It specializes in the strategic development, management and analysis of programs that support Clinical Development -from compound selection to Phase I-IV clinical studies.
交易背景
Icon hopes to expand its business in China and Asia-Pacific market, to meet the growing needs of R&D in China from global customers.
Beijing Wits Medical Consulting Ltd was founded in 1997 in China, it is mainly engaged in providing clinical services (Phase I-IV clinical studies) to pharmaceutical, medical device and biotechnology companies.
交易过程中的挑战
Multiple parties were bidding for Beijing Wits. We started the process later.
We needed to work with the partner to make sure they understand Icon were their best partner in China.
Beijing Wits used to be a JV and the JV had to be dissolved first before the acquisition.
Coordinated different parties to assure timely closing of the transaction.
交易结果
BFC helped Icon to complete the acquisition of Beijing Wits in six months.
Beijing Wits has become a strong local service team for Icon and has brought good partnership with local research centers and regulatory authorities for Icon.

交易日期
Orbiepharm was established in 2008; it is a company committed to research and develop the innovative class one drugs for companion animal.
It is the market leader in the development of high quality companion animal pharmaceutical, diagnostic and service products in China.
交易背景
Orbiepharm wished to optimize the investor base, which could support its further growth.
The Management team hope to attract some sophisticated PE investors to help the company grow into a market leader.
交易过程中的挑战
The company size is small, with limited staff, and the leading class I drug product has not been approved yet.
Company animal market is growing rapidly, but is still very fragmented。
A proper incentive structure that can motivate the management team while giving the control to the PE investors.

交易结果
As the financial advisor, BFC help Orbiepharm find a right market position, build its valuation models, and made it very appealing to investors.
Received three term sheets for investment/Mas.
Designed a proper capital structure and incentive structure for the management team.
The transaction was successfully completed within six months.

交易日期
Tianjin Jing Ming was established in October 1995. It is a high-tech enterprise specialized in the research, development, manufacture and sale of ophthalmic medical devices and consumable products.
交易背景
The founder wanted to retire earlier, and wished to find a buyer who could support the growth of the company.
The main products has few competitions, and the gross margins of those products are high.
The company was expanding its business in Latin American market. The new buyer should be prepared to take over the Latin American market.
交易过程中的挑战
One of the main products needs a new GMP facility due to new CFDA regulatory guideline.
Needed to find a strategic buyer with an approved GMP facility to help the merged company to grow.
Helped the founder and the company find an acceptable long-term deal structure to insure growth and profitability in the long-term.
交易结果
As the financial advisor, BFC helped JM make project presentations and business plan, and build its valuation models.
BFC successfully introduced Grand Pharma, a Hong Kong-listed company, to acquire Tianjin Jing Ming.
Help build a competitive closing process to insure timely closing of the deal.
Copyright © bfcgroup All rights reserved.
全程策划 :企业服务网